Abstract
In August 2012, ziv-aflibercept (Zaltrap) was approved by the FDA for use in combination with FOLFIRI in certain oxaliplatin-refractory patients with mCRC. Read about the mechanism of action, key trials, and management strategies associated with this VEGF pathway targeted agent.
